This document is intended for Investment Professionals
This is a marketing communication. Please refer to the prospectus of the fund and to the key investor information document before making any final investment decisions.

ETF (UCITS compliant)

L&G Pharma Breakthrough UCITS ETF

USD Accumulating ETF Class

Fund aim

The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index"). Physical Full Replication: The fund aims to track the Index by buying and holding the same investments as the index, in broadly the same proportions, where this is practical. More information on the Index can be found on page 2 of this document.

Who is this fund for?

- This ETF is designed for investors looking to grow their money in an investment which can form part of their existing savings portfolio.
- Although investors can take their money out at any time, this ETF may not be appropriate for those who plan to withdraw their money within five years.
- This fund is not designed for investors who cannot afford more than a minimal loss of their investment.
- If you do not understand the information in this document, the key information document or the prospectus, we recommend that you seek additional information or advice to help you decide if this ETF is suitable for you.

Fund snapshot

- **Long-term allocation**
  Long-term value in a pharmaceutical sub-sector that benefits from certain commercial and regulatory incentives
- **High growth potential**
  Aims to capture the future growth opportunity in orphan drugs
- **Leveraging industry expertise**
  An index tracking investment strategy that is supported by a team of pharmaceutical experts
- **Does it have a sustainable objective?**
  The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.

Fund facts

Fund size	$29.2m
Listing date	23 Jan 2018
Base currency	USD
Domicile	Ireland


Index
Solactive Pharma Breakthrough Value Index Net TR USD

Index ticker
SOLBIOT

Replication method
Physical - full replication

Ongoing charge	0.49%

Performance (%) USD Accumulating class



	1 month	6 months	1 year	3 years	5 years
NAV	-5.08	9.76	16.87	44.32	15.13
Index	-5.08	9.99	17.33	46.35	17.58
Relative	+0.00	-0.23	-0.46	-2.03	-2.45

Rolling 12-month performance

To 30 September	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017
NAV	16.87	17.17	5.39	-1.00	-19.42	4.05	40.18	-21.13	-	-
Index	17.33	17.66	6.01	-0.72	-19.07	4.49	40.93	-20.60	-	-
Relative	-0.46	-0.49	-0.62	-0.28	-0.35	-0.44	-0.75	-0.53	-	-

Performance for the USD Accumulating ETF class, listed on 23 January 2018. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF.

Past performance is not a guide to the future.


Index breakdown

The breakdowns below relate to the Index. The ETF's portfolio may deviate from the below. All data source L&G unless otherwise stated. Totals may not sum to 100% due to rounding.



Currency (%)

USD	68.0
JPY	9.9
EUR	6.9
CHF	2.7
DKK	2.7
GBP	2.6
HKD	2.5
SEK	2.4
KRW	2.3



Sector (%)

Health Care	97.7
Materials	2.3



Top 10 constituents **27.0%**
Rest of Index **73.0%**
Number of constituents in Index **41**

Top 10 constituents (%)

Xeris Biopharma	2.9
United Therapeutics	2.9
Ligand Pharmaceuticals	2.8
Basilea Pharmaceutica Ltd	2.7
Genmab A/S	2.7
Eisai	2.6
Biogen Inc	2.6
Beone Medicines	2.6
AstraZeneca	2.6
Agios Pharmaceuticals	2.6

Country (%)

United States	60.8
Japan	9.9
United Kingdom	4.9
Switzerland	2.7
Denmark	2.7
Italy	2.5
Cayman Islands	2.5
Ireland	2.4
Sweden	2.4
Other	9.0

Index description

The Index is comprised of bio-technology companies which are publicly traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An "orphan drug" is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the total market value of the proportion of its shares that are publicly traded) and (2) it is sufficiently "liquid" (a measure of how actively its shares are traded on a daily basis).

The universe of companies out of which the Index selection is made is refreshed annually in April. However, the Index is reconstituted semi-annually in April and October in accordance with the full selection criteria and all companies are equally weighted within the Index. On a monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of the Index, the weights of all companies are adjusted so that they are again equally weighted within the Index.

Index fund management team

Celebrating 35+ Years

The skill set and expertise we have developed over 35+ years in index management has allowed us to continuously evolve our investment processes. The Index Fund Management team comprises 30 fund managers with an average experience of 15 years, supported by 33 broader team members. Management oversight is provided by Dave Barron, Global Head of Index, ETFs & Systematic Solutions. The team also has full access to the resources and research of other specialists within L&G, including economists and strategists.

Key risks

- The value of an investment and any income taken from it is not guaranteed and can go down as well as up; you may not get back the amount you originally invested.
- An investment in the ETF involves a significant degree of risk. Any decision to invest should be based on the information contained in the relevant prospectus. Prospective investors should obtain their own independent accounting, tax and legal advice and should consult their own professional advisers to ascertain the suitability of the ETF as an investment.
- The value of the shares in the ETF is directly affected by increases and decreases in the value of the Index. Accordingly the value of a share in the ETF may go up or down and a shareholder may lose some or the entire amount invested.
- The ETF's ability to closely track the Index will be affected by its ability to purchase and/or sell the Index constituents and any legal or regulatory restrictions or disruptions affecting them.
- The ETF's ability to closely track the Index will also be affected by transaction costs and taxes incurred when adjusting its investment portfolio generally and/or to mirror any periodic adjustments to the constituents of the Index. There can be no certainty that ETF shares can always be bought or sold on a stock exchange or that the market price at which the ETF shares may be traded on a stock exchange will reflect the performance of the Index.
- The ETF is subject to the risk that third party service providers (such as a bank entering into swaps with the ETF or the ETF's depositary) may go bankrupt or fail to pay money due to the ETF or return property belonging to the ETF.
- As the Index includes micro, small and medium-sized publicly traded companies, the ETF is subject to the risk that such companies may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies or the stock market as a whole.
- Companies that are actively engaged in the research, development and manufacture of orphan drugs are particularly vulnerable to the risk that, following lengthy and costly development periods, a drug may not ultimately enter into revenue-generating commercial production as a result of: (i) clinical trial failures, (ii) governmental intervention or refusal to grant appropriate approvals and/or licenses for clinical trials or commercial production and/or (iii) a lack of commercially viability. Additionally, the emergence of cheaper or more effective drugs could lead to a decline in the revenues of such companies. Such factors could lead to a decline in the value of the companies represented in the Index and therefore the ETF.
- There is no capital guarantee or protection on the value of the ETF. Investors can lose all the capital invested in the ETF.
- Please refer to the “Risk Factors” section of the Issuer’s Prospectus and the Fund Supplement.
- This Fund may have underlying investments that are valued in currencies that are different from the currency of this share class, in which case exchange rate fluctuations will impact the value of your investment. In addition, the return in the currency of this share class may be different to the return in your own currency.
- The Fund has a sustainability and/or ESG focus in its investment process which may i) limit the Fund’s exposure to or exclude certain companies, industries or sectors ii) impact the Fund’s investment performance compared to other funds that do not apply such criteria and, iii) differ from an investor’s own sustainability and/or ESG criteria.

For more information, please refer to the key investor information document on our website.

Risk and reward profile

1	2	3	**4**	5	6	7

Lower risk — Higher risk

Potentially lower rewards — Potentially higher rewards

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you. We have classified this product as class 4 out of 7, which is a medium risk class. This product does not include any protection from future market performance so you could lose some or all of your investment.

Be aware of currency risk. You may receive payments in a different currency, so the final return you will get depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above. The fund is not covered by an investor compensation scheme.Companies that are actively engaged in the research, development and manufacture of orphan drugs are particularly vulnerable to the risk that, following lengthy and costly development periods, a drug may not ultimately enter into revenue-generating commercial production. The value of the Fund may be affected by risks not in the SRI, including failure of a counterparty, custodian, issuer or index provider and derivative use.

Trading information

Exchange	Currency	ISIN	SEDOL	Ticker	Bloomberg
London Stock Exchange	USD	IE00BF0H7608	BF0H760	BIOT	BIOT LN
London Stock Exchange	GBP	IE00BF0H7608	BDT5BG9	BIGT	BIGT LN
Borsa Italiana	EUR	IE00BF0H7608	BDVP3M7	BIOT	BIOT IM
Deutsche Börse	EUR	IE00BF0H7608	BDVP3N8	ETLI	ETLI GY
Euronext Amsterdam	EUR	IE00BF0H7608	BDVP3P0	BIOT	BIOT NA
SIX Swiss Exchange	CHF	IE00BF0H7608	BMG6942	BIOT	BIOT SW

The currency shown is the trading currency of the listing.

Country registration

Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom

Important information

A copy of the English version of the prospectus of the Fund is available on LGIM Fund Centre and may also be obtained from Legal & General Investment Management, 5 George's Dock Dublin 1, Ireland, D01 X8N7. Where required under national rules, the key information document will also be available in the local language of the relevant EEA Member State. A summary of investor rights associated with an investment in the Fund shall be available from www.lgim.com/investor_rights

We are also obliged to disclose that the Management Company has the right to terminate the arrangements made for marketing.

A decision may be taken at any time to terminate the arrangements made for the marketing of the Fund in any EEA Member State in which it is currently marketed. In such circumstances, Shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the Fund free of any charges or deductions for at least 30 working days from the date of such notification.

This is a marketing communication. Please refer to the prospectus of the Fund and to the KID before making any final investment decisions.

In the United Kingdom and outside the European Economic Area, this document is issued by Legal & General Investment Management Limited, authorised and regulated by the Financial Conduct Authority, No. 119272. Registered in England and Wales No. 02091894 with registered office at One Coleman Street, London, EC2R 5AA.

In the European Economic Area, this document is issued by LGIM Managers (Europe) Limited, authorised by the Central Bank of Ireland as a UCITS management company (pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (S.I. No. 352 of 2011), as amended) and as an alternative investment fund manager with "top up" permissions which enable the firm to carry out certain additional MiFID investment services (pursuant to the European Union (Alternative Investment Fund Managers) Regulations 2013 (S.I. No. 257 of 2013), as amended). Registered in Ireland with the Companies Registration Office (No. 609677). Registered Office: 70 Sir John Rogerson's Quay, Dublin, 2, Ireland. Regulated by the Central Bank of Ireland (No. C173733).

LGIM Managers (Europe) Limited operates a branch network in the European Economic Area, which is subject to supervision by the Central Bank of Ireland. In Italy, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Commissione Nazionale per le società e la Borsa ("CONSOB") and is registered with Banca d'Italia (no. 23978.0) with registered office at Piazza della Repubblica 3, Milano 20121, (Companies' Register no. MI - 2557936). In Germany, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the German Federal Financial Supervisory Authority ("BaFin"). In the Netherlands, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Dutch Authority for the Financial Markets ("AFM") and it is included in the register held by the AFM and registered with the trade register of the Chamber of Commerce under number 74481231. Details about the full extent of our relevant authorisations and permissions are available from us upon request. For further information on our products (including the product prospectuses), please visit our website.

The shares (the "Shares") discussed in this document are issued in relation to the relevant sub-fund (or share class(es) thereof) described in this document (together, the "Fund").

Copyright © 2026 Legal & General. This document is subject to copyright. Any unauthorised use is strictly prohibited. All rights are reserved.

No investment advice: We are required to clarify that we are not acting for you in any way in relation to the investment or investment activity to which this document relates. In particular, we will not provide any investment services to you and or advise you on the merits of, or make any recommendation to you in relation to, the terms of any transaction. None of our representatives are authorised to behave in any way which would lead you to believe otherwise. We are not, therefore, responsible for providing you with the protections afforded to some of our clients and you should seek your own independent legal, investment and tax or other advice as you see fit.

United States information: This document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the Fund or the Shares are authorised or registered for distribution and where no prospectus of the Fund has been filed with any securities commission or regulatory authority. Neither this document nor any copy hereof should be taken, transmitted or distributed (directly or indirectly) into the United States. Neither the Fund nor any of the Shares have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

No guarantee of accuracy: This document may contain independent market commentary prepared by us based on publicly available information. We do not warrant, guarantee or otherwise confirm the accuracy or correctness of any information contained herein and any opinions related to product or market activity may change. Any third party data providers used to source the information in this document make no warranties or claims of any kind relating to such data.

Historical performance is no indication of future performance: Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. However, back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance.

No offer for sale: The information contained in this document is neither an offer for sale nor a solicitation of an offer to buy securities. This document should not be used as the basis for any investment decision.

Risk Warnings: The Shares are products involving a significant degree of risk and may not be suitable for all types of investor. Any decision to invest should be based on the information contained in the prospectus of the Fund (or any supplements thereto) which includes, inter alia, information on certain risks associated with an investment. The price of any securities may go up or down and an investor may not get back the amount invested. Investors should only invest in a currency-hedged share class if they are willing to forego potential gains from appreciations in the currencies in which the Fund's assets are denominated against the currency of denomination of the relevant hedged share class. Currency hedging employed with respect to the hedged share classes aims to reduce currency risk rather than to eliminate it completely. Investors should also refer to the risk factor entitled "Currency" in the section of the Prospectus entitled "Risk Factors".

Prospectus: Investors should refer to the section entitled "Risk Factors" in the Fund's prospectus for further details of these and other risks associated with an investment in the Shares. The information in this document is designed solely for use in the relevant countries in which the Fund has been registered for public distribution and is not intended for residents of any other countries. The distribution of the prospectus and the offering, sale and delivery of Shares in other jurisdictions may be restricted by law.

For United Kingdom investors: The Fund is a recognised scheme under section 264 of the Financial Services and Markets Act 2000 and so the prospectus may be distributed to investors in the United Kingdom. Copies of all documents (i.e. the prospectus, the key investor information document, the latest annual audited report and financial statements and semi-annual unaudited report and financial statements and the constitution) are available in the United Kingdom from www.lgim.com.

For Austrian investors: Investors should base their investment decision only on the relevant prospectus, the Key Information Document, any supplements or addenda thereto, copies of the Memorandum and Articles of Association and the annual and semi-annual report, which can be obtained free of charge upon request at the Paying and Information Agent in Austria, Erste Bank der oesterreichischen Sparkassen AG, Graben 21, 1010 Wien, Österreich and on www.lgim.com.

For Dutch investors: The Fund has been registered with the Netherlands Authority for the Financial Markets following the UCITS passport-procedure pursuant to section 2:72 of the Dutch Financial Supervision Act.

For French investors: In France, this material is intended exclusively for professional investors (as defined under the MIFID) investing for their own account and this material may not in any way be distributed to the public. The Fund is a UCITS governed by Irish legislation and approved by the Central Bank of Ireland as UCITS compliant with European regulations although may not have to comply with the same rules as those applicable to a similar product approved in France. The Fund has been registered for marketing in France by the Authority Financial Markets (Autorité des Marchés Financiers) and may be distributed to investors in France. Copies of all documents (i.e. the prospectus, any supplements or addenda thereto, the latest annual reports, the memorandum of incorporation and articles of association and Key Information Document) are available in France, free of charge, at the French Centralizing Agent, Société Générale, Securities Services, at 1-5 rue du Débarcadère, 92700 Colombes - France. Any subscription for Shares

of the Fund will be made on the basis of the terms of the prospectus and any supplements or addenda thereto.

For German investors: Investors should base their investment decision only on the relevant prospectus and the Key Information Document. The offering of the Shares of the Fund has been notified to the German Financial Services Supervisory Authority (BaFin) in accordance with section 310 of the German Investment Code (KAGB). The Key Information Document (in the German language), the prospectus, any supplements or addenda thereto, copies of the Memorandum and Articles of Association and the annual and semi-annual report, can be obtained free of charge upon request at the Paying and Information Agent in Germany, HSBC Trinkaus & Burkhardt AG, Königsallee 21-23, 40212 Düsseldorf and on www.lgim.com. The current offering and redemption prices as well as the net asset value and possible notifications of the investors can also be requested free of charge at the same address. This document is a marketing communication within the meaning of Section 63 para. 6 of the German Securities Trading Act (WpHG). It is not investment research within the meaning of Art. 36 of the Commission Delegated Regulation (EU) 2017/565 and therefore does not meet all legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

For Norwegian Investors: The Fund has been registered with the Financial Supervisory Authority of Norway (Finanstilsynet), and may be marketed and sold to professional investors in Norway.

For Swiss investors: The Fund described in this document will be distributed in Switzerland exclusively to qualified investors as defined in the Swiss Collective Investment Schemes Act and its implementing ordinance. The prospectus for Switzerland, the key information documents, the Constitution, as well as the annual and semi-annual reports may be obtained free of charge from the current representative in Switzerland, FIRST INDEPENDENT FUND SERVICES LTD., Feldeggstrasse 12, 8008 Zurich. The paying agent in Switzerland is NPB Neue Privat Bank AG, Limmatquai 1, 8001 Zurich. As regards distribution in Switzerland, the place of jurisdiction and performance is at the registered seat of the representative.

L&G's asset management division is a major global investor across public and private markets, with €1,416.1 billion in assets under management (as at 30 June, 2026). Our investment philosophy and processes are designed to create value over the long term. We believe that incorporating financially material sustainability criteria, when relevant to our clients, can create attractive returns and drive positive change.

Source: L&G internal data as at 30 June 2026. The AUM disclosed aggregates the assets managed by L&G in the UK, LGIMA in the US and L&G Asia in Hong Kong (2018-2019 only). The AUM includes the value of securities and derivatives positions.

Contact us

Email **fundsales@lgim.com** Visit **lgim.com**

Index disclaimer

The L&G Pharma Breakthrough UCITS ETF (the "ETF") is not sponsored, promoted, sold or supported by Solactive AG. Nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Index and/or Index trade mark or the Index price, at any time or in any other respect.

The Solactive Pharma Breakthrough Value Index (the "Index") is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards the Legal & General UCITS ETF Plc, Solactive AG has no obligation to point out errors in the Index to third parties including, but not limited to, investors and/or financial intermediaries of the ETF. Solactive AG does not guarantee the accuracy and/or the completeness of the Index or any related data, and shall not have any liability for any errors, omissions or interruptions therein.

Neither publication of the Index by Solactive AG, nor the licensing of the Index or Index trade mark, for the purpose of use in connection with the ETF, constitutes a recommendation by Solactive AG to invest capital in said ETF nor does it, in any way, represent an assurance or opinion of Solactive AG with regard to any investment in this ETF. In no event shall Solactive AG have any liability for any lost profits or indirect, punitive, special or consequential damages or losses, even if notified of the possibility thereof.